Table 4.
Differences between patients with regression of relative wall thickness (RWT) and in whom RWT was stable or increased. p Values of statistical significance (<0.05) and tendency (0.05–0.1) are shown
| Decrease of RWT, n = 41 | Increase or stabilization of RWT, n = 45 | p | |
|---|---|---|---|
| ∆ WC (cm) | −1.5 (−23.5–8.5) | 0 (−8–18.5) | 0.029 |
| ∆TG/HDL | −0.10 (−5.77–1.47) | −0.07 (−1.59–4.41) | 0.03 |
| ∆LVMi (g/m 2.7) | −7.4±7.3 | 0.5±6.6 | < 0.0001 |
| ∆ urinary albumin excretion (mg/24h) | −3.4 (−269.4–52) | −0.9 (−103.3–128) | 0.1 |
| RWT1 (mm) | 0.38 (0.23–0.67) | 0.32 (0.25–0.41) | 0.0001 |
| RWT2 (mm) | 0.33 (0.21–0.46) | 0.36 (0.29–0.49) | < 0.001 |
| LVMi1 (g/m2.7) | 41.7±10.1 | 35.5±10.6 | 0.008 |
| LVMi2 (g/m 2.7) | 34.2±6.8 | 36.2±8.2 | ns |
| Number of patients with metabolic syndrome at start of treatment | 7* | 6 | ns |
| Number of patients with metabolic syndrome after 12 months of treatment | 1* | 5 | ns |
RWT, relative wall thickness (RWT1, at start of treatment; RWT2, after 12 months of treatment); n, number of patients; WC, waist circumference; TG/HDL, triglycerides to high-density lipoprotein cholesterol ratio; LVMi, left ventricular mass index; LVMi1, at start of treatment; LVMi2, after 12 months of treatment
*p = 0.04, Chi-squared = 4.17